{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:18Z","timestamp":1786979898293,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Coley Pharmaceutical Group, Inc.","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00262-019-02320-0","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T01:12:42Z","timestamp":1552093962000},"page":"1025-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Autologous tumor cell vaccination combined with systemic CpG-B and IFN-\u03b1 promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-5132","authenticated-orcid":false,"given":"Bas D.","family":"Koster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-4402","authenticated-orcid":false,"given":"Saskia J. A. M.","family":"Santegoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorien","family":"Harting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Baars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Marieke","family":"van Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik J.","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4482-2191","authenticated-orcid":false,"given":"Erik","family":"Hooijberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-8978","authenticated-orcid":false,"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2196-1233","authenticated-orcid":false,"given":"Alfons J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000281537","volume":"44","author":"A Yagoda","year":"1989","unstructured":"Yagoda A, Bander NH (1989) Failure of cytotoxic chemotherapy, 1983\u20131988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44:338\u2013345. \n                    https:\/\/doi.org\/10.1159\/000281537","journal-title":"Urol Int"},{"key":"2320_CR2","first-page":"CD001425","volume-title":"Cochrane database of systematic reviews","author":"C Coppin","year":"2004","unstructured":"Coppin C, Porzsolt F, Autenrieth M et al (2004) Immunotherapy for advanced renal cell cancer. In: Coppin C (ed) Cochrane database of systematic reviews. Wiley, Chichester, p\u00a0CD001425"},{"key":"2320_CR3","doi-asserted-by":"publisher","first-page":"e000185","DOI":"10.1136\/esmoopen-2017-000185","volume":"2","author":"A Rodriguez-Vida","year":"2017","unstructured":"Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH (2017) New treatment options for metastatic renal cell carcinoma. ESMO Open 2:e000185. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2017-000185","journal-title":"ESMO Open"},{"key":"2320_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"2320_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69\u201374. \n                    https:\/\/doi.org\/10.1126\/science.aaa4971","journal-title":"Science"},{"key":"2320_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","volume":"39","author":"BP Keenan","year":"2012","unstructured":"Keenan BP, Jaffee EM (2012) Whole cell vaccines\u2013past progress and future strategies. Semin Oncol 39:276\u2013286. \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2012.02.007","journal-title":"Semin Oncol"},{"key":"2320_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF01741726","volume":"32","author":"CS McCune","year":"1990","unstructured":"McCune CS, O\u2019Donnell RW, Marquis DM, Sahasrabudhe DM (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32:62\u201366","journal-title":"Cancer Immunol Immunother"},{"key":"2320_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0140-6736(04)15590-6","volume":"363","author":"D Jocham","year":"2004","unstructured":"Jocham D, Richter A, Hoffmann L et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594\u2013599. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(04)15590-6","journal-title":"Lancet"},{"key":"2320_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-009-0784-6","volume":"59","author":"M May","year":"2010","unstructured":"May M, Brookman-May S, Hoschke B et al (2010) 10-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 59:687\u2013695. \n                    https:\/\/doi.org\/10.1007\/s00262-009-0784-6","journal-title":"Cancer Immunol Immunother"},{"key":"2320_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.1993.11.3.390","volume":"11","author":"HC Hoover","year":"1993","unstructured":"Hoover HC, Brandhorst JS, Peters LC et al (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390\u2013399. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.3.390","journal-title":"J Clin Oncol"},{"key":"2320_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.2004.06.043","volume":"22","author":"D Berd","year":"2004","unstructured":"Berd D, Sato T, Maguire HC et al (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403\u2013415. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.06.043","journal-title":"J Clin Oncol"},{"key":"2320_CR12","first-page":"5160","volume":"59","author":"JW Simons","year":"1999","unstructured":"Simons JW, Mikhak B, Chang JF et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160\u20135168","journal-title":"Cancer Res"},{"key":"2320_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(98)07186-4","volume":"353","author":"JB Vermorken","year":"1999","unstructured":"Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345\u2013350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(98)07186-4","journal-title":"Lancet"},{"key":"2320_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1023\/A:1008363601515","volume":"11","author":"A Baars","year":"2000","unstructured":"Baars A, Claessen AM, van den Eertwegh AJ et al (2000) Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol Off J Eur Soc Med Oncol 11:965\u2013970","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2320_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/sj.bjc.6600254","volume":"86","author":"A Baars","year":"2002","unstructured":"Baars A, Claessen AME, Wagstaff J et al (2002) A phase II study of active specific immunotherapy and 5-FU\/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230\u20131234. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600254","journal-title":"Br J Cancer"},{"key":"2320_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/nat.2012.0340","volume":"22","author":"AM Krieg","year":"2012","unstructured":"Krieg AM (2012) CpG still rocks! update on an accidental drug. Nucleic Acid Ther 22:77\u201389. \n                    https:\/\/doi.org\/10.1089\/nat.2012.0340","journal-title":"Nucleic Acid Ther"},{"key":"2320_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.onc.1210911","volume":"27","author":"AM Krieg","year":"2008","unstructured":"Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161\u2013167. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1210911","journal-title":"Oncogene"},{"key":"2320_CR18","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","volume":"21","author":"SA Halperin","year":"2003","unstructured":"Halperin SA, Van Nest G, Smith B et al (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461\u20132467","journal-title":"Vaccine"},{"key":"2320_CR19","doi-asserted-by":"publisher","first-page":"e8787","DOI":"10.1371\/journal.pone.0008787","volume":"5","author":"RD Ellis","year":"2010","unstructured":"Ellis RD, Martin LB, Shaffer D et al (2010) Phase 1 trial of the plasmodium falciparum blood stage vaccine MSP142-C1\/Alhydrogel with and without CPG 7909 in malaria na\u00efve adults. PLoS One 5:e8787. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0008787","journal-title":"PLoS One"},{"key":"2320_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI23373","volume":"115","author":"DE Speiser","year":"2005","unstructured":"Speiser DE, Li\u00e9nard D, Rufer N et al (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739\u2013746. \n                    https:\/\/doi.org\/10.1172\/JCI23373","journal-title":"J Clin Invest"},{"key":"2320_CR21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/CJI.0b013e3181f1d614","volume":"33","author":"DE Speiser","year":"2010","unstructured":"Speiser DE, Schwarz K, Baumgaertner P et al (2010) Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 33:848\u2013858. \n                    https:\/\/doi.org\/10.1097\/CJI.0b013e3181f1d614","journal-title":"J Immunother"},{"key":"2320_CR22","doi-asserted-by":"publisher","first-page":"NA-NA","DOI":"10.1002\/ijc.24850","volume":"126","author":"J Karbach","year":"2009","unstructured":"Karbach J, Gnjatic S, Bender A et al (2009) Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide\u00ae ISA-51: Association with survival. Int J Cancer 126:NA-NA. \n                    https:\/\/doi.org\/10.1002\/ijc.24850","journal-title":"Int J Cancer"},{"key":"2320_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1158\/1078-0432.CCR-10-1811","volume":"17","author":"J Karbach","year":"2011","unstructured":"Karbach J, Neumann A, Atmaca A et al (2011) Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res 17:861\u2013870. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1811","journal-title":"Clin Cancer Res"},{"key":"2320_CR24","first-page":"1353","volume":"39","author":"LC Peters","year":"1979","unstructured":"Peters LC, Brandhorst JS, Hanna MG (1979) Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353\u20131360","journal-title":"Cancer Res"},{"key":"2320_CR25","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-07-4711","volume":"14","author":"BG Molenkamp","year":"2008","unstructured":"Molenkamp BG, Sluijter BJR, van Leeuwen PAM et al (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532\u20134542. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4711","journal-title":"Clin Cancer Res"},{"key":"2320_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, F\u00f6rster R et al (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708\u2013712. \n                    https:\/\/doi.org\/10.1038\/44385","journal-title":"Nature"},{"key":"2320_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/intimm\/dxm014","volume":"19","author":"SE Allan","year":"2007","unstructured":"Allan SE, Crome SQ, Crellin NK et al (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345\u2013354. \n                    https:\/\/doi.org\/10.1093\/intimm\/dxm014","journal-title":"Int Immunol"},{"key":"2320_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/eji.200636435","volume":"37","author":"J Wang","year":"2007","unstructured":"Wang J, Ioan-Facsinay A, van\u2020\u201eder\u2020\u201eVoort EIH et al (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37:129\u2013138. \n                    https:\/\/doi.org\/10.1002\/eji.200636435","journal-title":"Eur J Immunol"},{"key":"2320_CR29","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1073\/pnas.0509484103","volume":"103","author":"MA Gavin","year":"2006","unstructured":"Gavin MA, Torgerson TR, Houston E et al (2006) Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103:6659\u20136664. \n                    https:\/\/doi.org\/10.1073\/pnas.0509484103","journal-title":"Proc Natl Acad Sci USA"},{"key":"2320_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0394632017734459","volume":"30","author":"CM Huijts","year":"2017","unstructured":"Huijts CM, Santegoets SJ, de Jong TD et al (2017) Immunological effects of everolimus in patients with metastatic renal cell cancer. Int J Immunopathol Pharmacol 30:341\u2013352. \n                    https:\/\/doi.org\/10.1177\/0394632017734459","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2320_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.194.12.1823","volume":"194","author":"A Dzionek","year":"2001","unstructured":"Dzionek A (2001) BDCA-2, a Novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction. J Exp Med 194:1823\u20131834. \n                    https:\/\/doi.org\/10.1084\/jem.194.12.1823","journal-title":"J Exp Med"},{"key":"2320_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1189\/jlb.3MA0117-037R","volume":"102","author":"N Leeuwen-Kerkhoff van","year":"2017","unstructured":"van Leeuwen-Kerkhoff N, Lundberg K, Westers TM et al (2017) Transcriptional profiling reveals functional dichotomy between human slan + non-classical monocytes and myeloid dendritic cells. J Leukoc Biol 102:1055\u20131068. \n                    https:\/\/doi.org\/10.1189\/jlb.3MA0117-037R","journal-title":"J Leukoc Biol"},{"key":"2320_CR33","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4","volume":"28","author":"K Sch\u00e4kel","year":"1998","unstructured":"Sch\u00e4kel K, Mayer E, Federle C, et al (1998) A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 28:4084\u20134093. \n                    https:\/\/doi.org\/10.1002\/(SICI)1521-4141(199812)28:12%3C4084::AID-IMMU4084%3E3.0.CO;2-4","journal-title":"Eur J Immunol"},{"key":"2320_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(02)00393-X","volume":"17","author":"K Sch\u00e4kel","year":"2002","unstructured":"Sch\u00e4kel K, Kannagi R, Kniep B et al (2002) 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17:289\u2013301","journal-title":"Immunity"},{"key":"2320_CR35","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1158\/1078-0432.CCR-08-0656","volume":"14","author":"H Cruijsen van","year":"2008","unstructured":"van Cruijsen H, van der Veldt AAM, Vroling L et al (2008) Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14:5884\u20135892. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0656","journal-title":"Clin Cancer Res"},{"key":"2320_CR36","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","volume":"25","author":"P Filipazzi","year":"2007","unstructured":"Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor\u2013based antitumor vaccine. J Clin Oncol 25:2546\u20132553. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.08.5829","journal-title":"J Clin Oncol"},{"key":"2320_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","volume":"2","author":"SJ Santegoets","year":"2014","unstructured":"Santegoets SJ, Stam AG, Lougheed SM et al (2014) Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother cancer 2:31. \n                    https:\/\/doi.org\/10.1186\/s40425-014-0031-3","journal-title":"J Immunother cancer"},{"key":"2320_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM197509042931013","volume":"293","author":"JE Sokal","year":"1975","unstructured":"Sokal JE (1975) Measurement of delayed skin-test responses. N Engl J Med 293:501\u2013502. \n                    https:\/\/doi.org\/10.1056\/NEJM197509042931013","journal-title":"N Engl J Med"},{"key":"2320_CR39","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/sj.bjc.6600254","volume":"86","author":"A Baars","year":"2002","unstructured":"Baars A, Claessen A, Wagstaff J et al (2002) A phase II study of active specific immunotherapy and 5-FU\/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230\u20131234. \n                    https:\/\/doi.org\/10.1038\/sj\/bjc\/6600254","journal-title":"Br J Cancer"},{"key":"2320_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CJI.0b013e31823731a4","volume":"35","author":"RC Harris","year":"2012","unstructured":"Harris RC, Chianese-Bullock KA, Petroni GR et al (2012) The vaccine-site microenvironment induced by injection of incomplete freund\u02bcs adjuvant, with or without melanoma peptides. J Immunother 35:78\u201388. \n                    https:\/\/doi.org\/10.1097\/CJI.0b013e31823731a4","journal-title":"J Immunother"},{"key":"2320_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N et al (2013) Persistent antigen at vaccination sites induces tumor-specific CD8 + T cell sequestration, dysfunction and deletion. Nat Med 19:465\u2013472. \n                    https:\/\/doi.org\/10.1038\/nm.3105","journal-title":"Nat Med"},{"key":"2320_CR42","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148\u20132157. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1332","journal-title":"Clin Cancer Res"},{"key":"2320_CR43","doi-asserted-by":"publisher","first-page":"e989764","DOI":"10.4161\/2162402X.2014.989764","volume":"4","author":"O Draghiciu","year":"2015","unstructured":"Draghiciu O, Nijman HW, Hoogeboom BN et al (2015) Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 4:e989764. \n                    https:\/\/doi.org\/10.4161\/2162402X.2014.989764","journal-title":"Oncoimmunology"},{"key":"2320_CR44","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2326-6066.CIR-14-0076","volume":"2","author":"B Farsaci","year":"2014","unstructured":"Farsaci B, Donahue RN, Coplin MA et al (2014) Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2:1090\u20131102. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0076","journal-title":"Cancer Immunol Res"},{"key":"2320_CR45","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","volume":"17","author":"BI Rini","year":"2016","unstructured":"Rini BI, Stenzl A, Zdrojowy R et al (2016) IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17:1599\u20131611. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30408-9","journal-title":"Lancet Oncol"},{"key":"2320_CR46","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","volume":"14","author":"JH Finke","year":"2008","unstructured":"Finke JH, Rini B, Ireland J et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674\u20136682. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5212","journal-title":"Clin Cancer Res"},{"key":"2320_CR47","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","volume":"70","author":"JS Ko","year":"2010","unstructured":"Ko JS, Rayman P, Ireland J et al (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526\u20133536. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3278","journal-title":"Cancer Res"},{"key":"2320_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A, Parkhurst MR, Tran E et al (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22:433\u2013438. \n                    https:\/\/doi.org\/10.1038\/nm.4051","journal-title":"Nat Med"},{"key":"2320_CR49","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463\u20131469. \n                    https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"key":"2320_CR50","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(05)60748-9","volume":"352","author":"L H\u00f6ltl","year":"1998","unstructured":"H\u00f6ltl L, Rieser C, Papesh C et al (1998) CD83 + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358","journal-title":"Lancet"},{"key":"2320_CR51","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1158\/0008-5472.CAN-05-3905","volume":"66","author":"J Wierecky","year":"2006","unstructured":"Wierecky J, M\u00fcller MR, Wirths S et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910\u20135918. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3905","journal-title":"Cancer Res"},{"key":"2320_CR52","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.2883","volume":"18","author":"S Walter","year":"2012","unstructured":"Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254\u20131261. \n                    https:\/\/doi.org\/10.1038\/nm.2883","journal-title":"Nat Med"},{"key":"2320_CR53","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8 + and CD4 + immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19:990\u2013999. \n                    https:\/\/doi.org\/10.1038\/mt.2010.289","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.1007\/s00262-019-02328-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02320-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T19:06:47Z","timestamp":1583608007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02320-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02320-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"1 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article the following abstract and keywords\u00a0were inadvertently omitted.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of the Vrije Universiteit (VU) University Medical Center (reference number 2003-37.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written-informed consent to participate in the clinical trial and to use their data for research and publication purposes was obtained from each patient before treatment in accordance with the Declaration of Helsinki. The trial was not prospectively registered in a public trial registry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}